Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy

INTRODUCTION: The anti-CD20 antibody rituximab (RTX) has substantially improved outcomes of patients with B-cell lymphomas, although more efficient therapies are needed for refractory or relapsing lymphomas. An approach to increase the clinical effectiveness of anti-tumor therapy is the use of antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Casadesús, Ana Victoria, Cruz, Beatriz María, Díaz, Wilden, González, Miguel Ángel, Gómez, Tania, Fernández, Briandy, González, Addys, Ledón, Nuris, Sosa, Katya, Castro, Kathleen, López, Armando, Plasencia, Claudia, Ramírez, Yaima, Teillaud, Jean-Luc, Hernández, Calixto, León, Kalet, Hernández, Tays
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780377/
https://www.ncbi.nlm.nih.gov/pubmed/36569901
http://dx.doi.org/10.3389/fimmu.2022.1021828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780377/
https://www.ncbi.nlm.nih.gov/pubmed/36569901
http://dx.doi.org/10.3389/fimmu.2022.1021828

Ejemplares similares